Ulta's CEO Said the GLP-1 Craze Has Created New Demand for Certain Hair and Skincare Products

Why It Matters

The shift links pharmaceutical trends to beauty retail demand, reshaping category growth and inventory strategies. It also opens broader market opportunities as weight‑loss drugs become mainstream.

Key Takeaways

• GLP-1 users driving demand for anti‑hair loss products
• Skin elasticity treatments see surge among rapid‑weight‑loss consumers
• Ulta’s skincare and hair care now 43% of sales
• 10% of U.S. population on GLP‑1 weight‑loss drugs
• Ulta stock up 50% year‑over‑year

Pulse Analysis

The rapid adoption of GLP‑1 agonists such as Ozempic and Wegovy has turned a medical breakthrough into a cultural phenomenon. While these drugs deliver impressive weight‑loss results, side effects like hair thinning and reduced skin elasticity have sparked a new consumer need. Beauty shoppers, especially those experiencing the so‑called “Ozempic face,” are now actively searching for products that restore volume and strengthen follicles, creating a niche demand that extends beyond traditional anti‑aging segments.

Ulta Beauty is capitalising on this shift by positioning its hair‑care and skincare lines as solutions for GLP‑1‑related concerns. With skincare, wellness and hair care already representing 43% of its $12.39 billion 2025 revenue, the retailer’s product mix aligns perfectly with the emerging demand. The company’s stock has appreciated roughly 50% in the past year, reflecting investor confidence that Ulta can capture this growth. By leveraging in‑store expertise and a broad brand portfolio, Ulta can quickly surface targeted treatments, from biotin‑rich shampoos to collagen‑boosting serums, to meet the needs of a rapidly expanding customer base.

The broader beauty industry is taking note, as pharmaceutical firms and cosmetic brands launch filler treatments and specialized moisturisers to address the aesthetic side effects of weight‑loss drugs. This convergence of health and beauty signals a lasting change in consumer behaviour, where medication-driven body transformations drive ancillary product categories. Retailers that integrate medical insights with curated product assortments are likely to gain a competitive edge, while analysts will watch how sustained GLP‑1 usage reshapes long‑term category forecasts.